Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 9, 2013, Pages 1322-1334

  Eckert, Mark A ^a   Vu, Quynh ^a   Xie, Kate ^a   Yu, Jingxia ^a   Liao, Wenbin ^b   Cramer, Steven C ^a   Zhao, Weian ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

ischemia; mesenchymal stem cells; mesenchymal stromal cells; MSC; regenerative therapy; stroke

Indexed keywords

NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR;

ANGIOGENESIS; BONE MARROW CELL; BRAIN ISCHEMIA; CELL THERAPY; CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; ENDOTHELIAL PROGENITOR CELL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; MESENCHYMAL STROMA CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT;

BRAIN ISCHEMIA; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; RECOVERY OF FUNCTION; STROKE; TISSUE THERAPY;

EID: 84883739647     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.91     Document Type: Review

References (190)

1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371: 1612-1623. (Pubitemid 351626845)
2. NCHS Dataline. Public Health Reports. 126: 433.
3. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol 2009; 8: 345-354.
4. Teasell RW. Long-term sequelae of stroke: how should you handle stroke complications? Can Fam Physician 1992; 38: 381-388.
5. Mauldin PD, Simpson KN, Palesch YY, Spilker JS, Hill MD, Khatri P et al. Design of the economic evaluation for the Interventional Management of Stroke (III) trial. Int J Stroke 2008; 3: 138-144. (Pubitemid 351566848)
6. Ansari S, Rahman M, Waters MF, Hoh BL, Mocco J. Recanalization therapy for acute ischemic stroke, part 1: surgical embolectomy and chemical thrombolysis. Neurosurg Rev 2011; 34: 1-9.
7. Ansari S, Rahman M, McConnell DJ, Waters MF, Hoh BL, Mocco J. Recanalization therapy for acute ischemic stroke, part 2: mechanical intra-arterial technologies. Neurosurg Rev 2011; 34: 11-20.
8. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011; 42: 1952-1955.
9. Trounson A. New perspectives in human stem cell therapeutic research. BMC Med 2009; 7: 29.
10. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
11. Mohal JS, Tailor HD, Khan WS. Sources of adult mesenchymal stem cells and their applicability for musculoskeletal applications. Curr Stem Cell Res Ther 2012; 7: 103-109.
12. Witkowska-Zimny M, Wrobel E. Perinatal sources of mesenchymal stem cells: Wharton's jelly, amnion and chorion. Cell Mol Biol Lett 2011; 16: 493-514.
13. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-736.
14. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA 1999; 96: 10711-10716. (Pubitemid 29442209)
15. Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 2000; 290: 1779-1782. (Pubitemid 32004811)
16. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 2000; 164: 247-256. (Pubitemid 32008970)
17. Deng W, Obrocka M, Fischer I, Prockop DJ. In vitro differentiation of human marrow stromal cells into early progenitors of neural cells by conditions that increase intracellular cyclic AMP. Biochem Biophys Res Commun 2001; 282: 148-152. (Pubitemid 32924357)
18. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007; 25: 2896-2902. (Pubitemid 350127874)
19. Brooke G, Cook M, Blair C, Han R, Heazlewood C, Jones B et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol 2007; 18: 846-858. (Pubitemid 350138458)
20. Dharmasaroja P. Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. J Clin Neurosci 2009; 16: 12-20.
21. Cyranoski D. Canada approves stem cell product. Nat Biotechnol 2012; 30: 571.
22. Honmou O, Onodera R, Sasaki M, Waxman SG, Kocsis JD. Mesenchymal stem cells: therapeutic outlook for stroke. Trends Mol Med 2012; 18: 292-297.
23. Googel S, Gubernator M, Minger SL. Progress and prospects: stem cells and neurological diseases. Gene Ther 2011; 18: 1-6.
24. Lindvall O, Kokaia Z. Stem cell research in stroke: how far from the clinic? Stroke 2011; 42: 2369-2375.
25. Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol 2012; 11: 369-380.
26. Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R. Mesenchymal stem cells for clinical application. Vox Sang 2010; 98: 93-107.
27. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557-564.
28. Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol 2012; 5: 19.
29. Vaes B, Van't Hof W, Deans R, Pinxteren J. Application of MultiStem(s) allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front Immunol 2012; 3: 345.
30. Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 2000; 61: 364-370. (Pubitemid 30620221)
31. Krabbe C, Zimmer J, Meyer M. Neural transdifferentiation of mesenchymal stem cells-a critical review. APMIS 2005; 113: 831-844. (Pubitemid 43934224)
32. Oswald J, Boxberger S, Jgensen B, Feldmann S, Ehninger G, Bornhauser M et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004; 22: 377-384. (Pubitemid 38736621)
33. Eglitis MA, Dawson D, Park KW, Mouradian MM. Targeting of marrow-derived astrocytes to the ischemic brain. Neuroreport 1999; 10: 1289-1292. (Pubitemid 29403711)
34. Bao X, Feng M, Wei J, Han Q, Zhao H, Li G et al. Transplantation of Flk-1\+ human bone marrow-derived mesenchymal stem cells promotes angiogenesis and neurogenesis after cerebral ischemia in rats. Eur J Neurosci 2011; 34: 87-98.
35. Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci 2001; 189: 49-57. (Pubitemid 32776649)
36. Li Y, Chopp M, Chen J, Wang L, Gautam SC, Xu YX et al. Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice. J Cereb Blood Flow Metab 2000; 20: 1311-1319.
37. Skvortsova VI, Gubskiy LV, Tairova RT, Povarova OV, Cheglakov IB, Holodenko RV et al. Use of bone marrow mesenchymal (stromal) stem cells in experimental ischemic stroke in rats. Bull Exp Biol Med 2008; 145: 122-128.
38. Zhao L-R, Duan W-M, Reyes M, Keene CD, Verfaillie CM, Low WC. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 2002; 174: 11-20. (Pubitemid 34218904)
39. Shichinohe H, Kuroda S, Yano S, Ohnishi T, Tamagami H, Hida K et al. Improved expression of gamma-aminobutyric acid receptor in mice with cerebral infarct and transplanted bone marrow stromal cells: an autoradiographic and histologic analysis. J Nucl Med 2006; 47: 486-491. (Pubitemid 46768491)
40. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001; 32: 1005-1011. (Pubitemid 32285175)
41. Hofstetter CP, Schwarz EJ, Hess D, Widenfalk J, El Manira A, Prockop DJ et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci USA 2002; 99: 2199-2204. (Pubitemid 34169038)
42. Ikeda N, Nonoguchi N, Zhao MZ, Watanabe T, Kajimoto Y, Furutama D et al. Bone marrow stromal cells that enhanced fibroblast growth factor-2 secretion by herpes simplex virus vector improve neurological outcome after transient focal cerebral ischemia in rats. Stroke 2005; 36: 2725-2730.
43. Kurozumi K, Nakamura K, Tamiya T, Kawano Y, Kobune M, Hirai S et al. BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. Mol Ther 2004; 9: 189-197. (Pubitemid 38256545)
44. Zhao M-Z, Nonoguchi N, Ikeda N, Watanabe T, Furutama D, Miyazawa D et al. Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J Cereb Blood Flow Metab 2006; 26: 1176-1188. (Pubitemid 44268180)
45. Cramer SC, Sur M, Dobkin BH, O'Brien C, Sanger TD, Trojanowski JQ et al. Harnessing neuroplasticity for clinical applications. Brain 2011; 134: 1591-1609.
46. Cramer SC. Repairing the human brain after stroke. II. Restorative therapies. Ann Neurol 2008; 63: 549-560.
47. Hilfiker A, Kasper C, Hass R, Haverich A. Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: is there a future for transplantation? Langenbecks Arch Surg 2011; 396: 489-497.
48. Miller RH, Bai L, Lennon DP, Caplan AI. The potential of mesenchymal stem cells for neural repair. Discov Med 2010; 9: 236-242.
49. Chen J, Li Y, Katakowski M, Chen X, Wang L, Lu D et al. Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res 2003; 73: 778-786. (Pubitemid 37071731)
50. Steffenhagen C, Dechant F-X, Oberbauer E, Furtner T, Weidner N, Kury P et al. Mesenchymal stem cells prime proliferating adult neural progenitors toward an oligodendrocyte fate. Stem Cells Dev 2012; 21: 1838-1851.
51. Mauri M, Lentini D, Gravati M, Foudah D, Biella G, Costa B et al. Mesenchymal stem cells enhance GABAergic transmission in co-cultured hippocampal neurons. Mol Cell Neurosci 2012; 49: 395-405.
52. Ribeiro CA, Salgado AJ, Fraga JS, Silva NA, Reis RL, Sousa N. The secretome of bone marrow mesenchymal stem cells-conditioned media varies with time and drives a distinct effect on mature neurons and glial cells (primary cultures). J Tissue Eng Regen Med 2011; 5: 668-672.
53. Zhang J, Zhang Y, Xing S, Liang Z, Zeng J. Secondary neurodegeneration in remote regions after focal cerebral infarction: a new target for stroke management? Stroke 2012; 43: 1700-1705.
54. Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 2002; 59: 514-523. (Pubitemid 34919983)
55. Shen LH, Li Y, Chopp M. Astrocytic endogenous glial cell derived neurotrophic factor production is enhanced by bone marrow stromal cell transplantation in the ischemic boundary zone after stroke in adult rats. Glia 2010; 58: 1074-1081.
56. Yilmaz G, Alexander JS, Erkuran Yilmaz C, Granger DN. Induction of neuroprotective/regenerative genes in stem cells infiltrating post-ischemic brain tissue. Exp Transl Stroke Med 2010; 2: 11.
57. Maltman DJ, Hardy SA, Przyborski SA. Role of mesenchymal stem cells in neurogenesis and nervous system repair. Neurochem Int 2011; 59: 347-356.
58. Sakai T, Johnson KJ, Murozono M, Sakai K, Magnuson MA, Wieloch T et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med 2001; 7: 324-330. (Pubitemid 32224348)
59. Iadecola C, Anrather J. The immunology of stroke: From mechanisms to translation. Nat Med 2011; 17: 796-808.
60. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843. (Pubitemid 34534559)
61. Nasef A, Mathieu N, Chapel A, Frick J, François S, Mazurier C et al. Immunosuppressive effects of mesenchymal stem cells: Involvement of HLA-G. Transplantation 2007; 84: 231-237. (Pubitemid 47205757)
62. Meisel R, Zibert A, Laryea M, Goobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619-4621. (Pubitemid 38745993)
63. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822. (Pubitemid 40223708)
64. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-398. (Pubitemid 44464808)
65. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48. (Pubitemid 34059216)
66. Bacigalupo A, Valle M, Podestà M, Pitto A, Zocchi E, De Flora A et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005; 33: 819-827. (Pubitemid 40826596)
67. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234. (Pubitemid 46053063)
68. Marigo I, Dazzi F. The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol 2011; 33: 593-602.
69. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372. (Pubitemid 43053565)
70. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105: 2214-2219. (Pubitemid 40731815)
71. Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzon IM, Nepomnaschy I et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS ONE 2010; 5: e9252.
72. Li Y, Chopp M. Marrow stromal cell transplantation in stroke and traumatic brain injury. Neurosci Lett 2009; 456: 120-123.
73. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010; 16: 203-209.
74. Oh JY, Roddy GW, Choi H, Lee RH, Ylostalo JH, Rosa RH et al. Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci USA 2010; 107: 16875-16880.
75. Ajmo CT, Vernon DOL, Collier L, Hall AA, Garbuzova-Davis S, Willing A et al. The spleen contributes to stroke-induced neurodegeneration. J Neurosci Res 2008; 86: 2227-2234.
76. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001; 169: 12-20. (Pubitemid 32437040)
77. Detante O, Moisan A, Dimastromatteo J, Richard M-J, Riou L, Grillon E et al. Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution. Cell Transplant 2009; 18: 1369-1379.
78. Isa A, Nehlin JO, Sabir HJ, Andersen TE, Gaster M, Kassem M et al. Impaired cell surface expression of HLA-B antigens on mesenchymal stem cells and muscle cell progenitors. PLoS ONE 2010; 5: e10900.
79. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896. (Pubitemid 37211373)
80. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EGA, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114-2120. (Pubitemid 44395028)
81. Vendrame M, Gemma C, De Mesquita D, Collier L, Bickford PC, Sanberg CD et al. Anti-inflammatory effects of human cord blood cells in a rat model of stroke. Stem Cells Dev 2005; 14: 595-604. (Pubitemid 41780811)
82. Mora-Lee S, Sirerol-Piquer MS, Gutierrez-Perez M, Gomez-Pinedo U, Roobrouck VD, Loopez T et al. Therapeutic effects of hMAPC and hMSC transplantation after stroke in mice. PLoS ONE 2012; 7: e43683.
83. Shi Y, Hu G, Su J, Li W, Chen Q, Shou P et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 2010; 20: 510-518.
84. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI et al. Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150. (Pubitemid 351181031)
85. Ren G, Su J, Zhang L, Zhao X, Ling W, L'huillie A et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27: 1954-1962.
86. Hwang JH, Shim SS, Seok OS, Lee HY, Woo SK, Kim BH et al. Comparison of cytokine expression in mesenchymal stem cells from human placenta, cord blood, and bone marrow. J Korean Med Sci 2009; 24: 547-554.
87. Scheibe F, Ladhoff J, Huck J, Grohmann M, Blazej K, Oersal A et al. Immune effects of mesenchymal stromal cells in experimental stroke. J Cereb Blood Flow Metab 2012; 32: 1578-1588.
88. Vogelgesang A, Dressel A. Immunological consequences of ischemic stroke: immunosuppression and autoimmunity. J Neuroimmunol 2011; 231: 105-110.
89. Schinkothe T, Bloch W, Schmidt A. In vitro secreting profile of human mesenchymal stem cells. Stem Cells Dev 2008; 17: 199-206.
90. Kagiwada H, Yashiki T, Ohshima A, Tadokoro M, Nagaya N, Ohgushi H. Human mesenchymal stem cells as a stable source of VEGF-producing cells. J Tissue Eng Regen Med 2008; 2: 184-189.
91. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004; 109: 1543-1549. (Pubitemid 38420184)
92. Ma Y, Zechariah A, Qu Y, Hermann DM. Effects of vascular endothelial growth factor in ischemic stroke. J Neurosci Res 2012; 90: 1873-1882.
93. Horie N, Pereira MP, Niizuma K, Sun G, Keren-Gill H, Encarnacion A et al. Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair. Stem Cells 2011; 29: 274-285.
94. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003; 111: 1843-1851. (Pubitemid 38057729)
95. Toma C, Wagner WR, Bowry S, Schwartz A, Villanueva F. Fate of cultureexpanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ Res 2009; 104: 398-402.
96. Fisher M. Pericyte signaling in the neurovascular unit. Stroke 2009; 40: S13-S15.
97. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 2010; 12: 87-117.
98. Cho YJ, Song HS, Bhang S, Lee S, Kang BG, Lee JC et al. Therapeutic effects of human adipose stem cell-conditioned medium on stroke. J Neurosci Res 2012; 90: 1794-1802.
99. Xin H, Li Y, Shen LH, Liu X, Wang X, Zhang J et al. Increasing tPA activity in astrocytes induced by multipotent mesenchymal stromal cells facilitate neurite outgrowth after stroke in the mouse. PLoS ONE 2010; 5: e9027.
100. Scheibe F, Klein O, Klose J, Priller J. Mesenchymal stromal cells rescue cortical neurons from apoptotic cell death in an in vitro model of cerebral ischemia. Cell Mol Neurobiol 2012; 32: 567-576.
101. Liu N, Zhang Y, Fan L, Yuan M, Du H, Cheng R et al. Effects of transplantation with bone marrow-derived mesenchymal stem cells modified by Survivin on experimental stroke in rats. J Transl Med 2011; 9: 105.
102. Zhang L, Li Y, Zhang C, Chopp M, Gosiewska A, Hong K. Delayed administration of human umbilical tissue-derived cells improved neurological functional recovery in a rodent model of focal ischemia. Stroke 2011; 42: 1437-1444.
103. Borlongan CV, Lind JG, Dillon-Carter O, Yu G, Hadman M, Cheng C et al. Bone marrow grafts restore cerebral blood flow and blood brain barrier in stroke rats. Brain Res 2004; 1010: 108-116. (Pubitemid 38569858)
104. Li Y, Chen J, Zhang CL, Wang L, Lu D, Katakowski M et al. Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia 2005; 49: 407-417. (Pubitemid 40222918)
105. Shen LH, Li Y, Chen J, Zacharek A, Gao Q, Kapke A et al. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab 2007; 27: 6-13. (Pubitemid 46006579)
106. Zhang J, Li Y, Chen J, Yang M, Katakowski M, Lu M et al. Expression of insulin-like growth factor 1 and receptor in ischemic rats treated with human marrow stromal cells. Brain Res 2004; 1030: 19-27. (Pubitemid 39563824)
107. Lin Y-C, Ko T-L, Shih Y-H, Lin M-YA, Fu T-W, Hsiao H-S et al. Human umbilical mesenchymal stem cells promote recovery after ischemic stroke. Stroke 2011; 42: 2045-2053.
108. Xin H, Li Y, Shen LH, Liu X, Hozeska-Solgot A, Zhang RL et al. Multipotent mesenchymal stromal cells increase tPA expression and concomitantly decrease PAI-1 expression in astrocytes through the sonic hedgehog signaling pathway after stroke (in vitro study). J Cereb Blood Flow Metab 2011; 31: 2181-2188.
109. Ross JJ, Verfaillie CM. Evaluation of neural plasticity in adult stem cells. Philos Trans R Soc Lond B Biol Sci 2008; 363: 199-205. (Pubitemid 350174573)
110. Koh S-H, Kim KS, Choi MR, Jung KH, Park KS, Chai YG et al. Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res 2008; 1229: 233-248.
111. Lim JY, Jeong CH, Jun JA, Kim SM, Ryu CH, Hou Y et al. Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia. Stem Cell Res Ther 2011; 2: 38.
112. Ikegame Y, Yamashita K, Hayashi S-I, Mizuno H, Tawada M, You F et al. Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy 2011; 13: 675-685.
113. Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307-316. (Pubitemid 30056419)
114. Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, Onodera R et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011; 134: 1790-1807.
115. Fan M, Chen W, Liu W, Du G-Q, Jiang S-L, Tian W-C et al. The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuventation Res 2010; 13: 429-438.
116. Wilson A, Shehadeh LA, Yu H, Webster KA. Age-related molecular genetic changes of murine bone marrow mesenchymal stem cells. BMC Genomics 2010; 11: 229.
117. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389-397. (Pubitemid 36222968)
118. Figueroa FE, Carrion F, Villanueva S, Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: A critical review. Biol Res 2012; 45: 269-277.
119. Li Y, McIntosh K, Chen J, Zhang C, Gao Q, Borneman J et al. Allogeneic bone marrow stromal cells promote glial-axonal remodeling without immunologic sensitization after stroke in rats. Exp Neurol 2006; 198: 313-325.
120. Hare JM, Fishman JE, Gerstenblith G, Difede Velazquez DL, Zambrano JP, Suncion VY et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012; 308: 1-11.
121. Zacharek A, Shehadah A, Chen J, Cui X, Roberts C, Lu M et al. Comparison of bone marrow stromal cells derived from stroke and normal rats for stroke treatment. Stroke 2010; 41: 524-530.
122. Ilic N, Brooke G, Murray P, Barlow S, Rossetti T, Pelekanos R et al. Manufacture of clinical grade human placenta-derived multipotent mesenchymal stromal cells. Methods Mol Biol 2011; 698: 89-106.
123. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-1301. (Pubitemid 44464698)
124. Lane TA, Garls D, Mackintosh E, Kohli S, Cramer SC. Liquid storage of marrow stromal cells. Transfusion 2009; 49: 1471-1481.
125. Colter DC, Sekiya I, Prockop DJ. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA 2001; 98: 7841-7845. (Pubitemid 32642648)
126. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000; 113(Pt 7): 1161-1166. (Pubitemid 30229533)
127. Li WY, Choi YJ, Lee PH, Huh K, Kang YM, Kim HS et al. Mesenchymal stem cells for ischemic stroke: Changes in effects after ex vivo culturing. Cell Transplant 2008; 17: 1045-1059.
128. Crisostomo PR, Wang M, Wairiuko GM, Morrell ED, Terrell AM, Seshadri P et al. High passage number of stem cells adversely affects stem cell activation and myocardial protection. Shock 2006; 26: 575-580. (Pubitemid 44789631)
129. Ng F, Boucher S, Koh S, Sastry KSR, Chase L, Lakshmipathy U et al. PDGF, TGFbeta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008; 112: 295-307.
130. Chase LG, Yang S, Zachar V, Yang Z, Lakshmipathy U, Bradford J et al. Development and characterization of a clinically compliant xeno-free culture medium in good manufacturing practice for human multipotent mesenchymal stem cells. Stem Cells Transl Med 2012; 1: 750-758.
131. Nold P, Brendel C, Neubauer A, Bein G, Hackstein H. Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. Biochem Biophys Res Commun 2012; 12: 02142-02150.
132. Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG, Frick J et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003; 5: 1028-1038. (Pubitemid 40310427)
133. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003; 100: 8407-8411. (Pubitemid 36842558)
134. Ahmadian Kia N, Bahrami AR, Ebrahimi M, Matin MM, Neshati Z, Almohaddesin MR et al. Comparative analysis of chemokine receptor's expression in mesenchymal stem cells derived from human bone marrow and adipose tissue. J Mol Neurosci 2011; 44: 178-185.
135. Tuttolomondo A, Di Raimondo D, Di Sciacca R, Pinto A, Licata G. Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des 2008; 14: 3574-3589.
136. Ponte AL, Marais E, Gallay N, Langonne A, Delorme B, Herault O et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007; 25: 1737-1745. (Pubitemid 47121852)
137. Raheja LF, Genetos DC, Wong A, Yellowley CE. Hypoxic regulation of mesenchymal stem cell migration: the role of RhoA and HIF-1a. Cell Biol Int 2011; 35: 981-989.
138. Hu X, Wei L, Taylor TM, Wei J, Zhou X, Wang J-A et al. Hypoxic preconditioning enhances bone marrow mesenchymal stem cell migration via Kv2.1 channel and FAK activation. Am J Physiol Cell Physiol 2011; 301: C362-C372.
139. Ohtani Y, Minami M, Kawaguchi N, Nishiyori A, Yamamoto J, Takami S et al. Expression of stromal cell-derived factor-1 and CXCR4 chemokine receptor mRNAs in cultured rat glial and neuronal cells. Neurosci Lett 1998; 249: 163-166. (Pubitemid 28331541)
140. Lu D-Y, Tang C-H, Yeh W-L, Wong K-L, Lin C-P, Chen Y-H et al. SDF-1alpha upregulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and NF-kappaBdependent pathway in microglia. Eur J Pharmacol 2009; 613: 146-154.
141. Kawabori M, Kuroda S, Sugiyama T, Ito M, Shichinohe H, Houkin K et al. Intracerebral, but not intravenous, transplantation of bone marrow stromal cells enhances functional recovery in rat cerebral infarct: an optical imaging study. Neuropathology 2012; 32: 217-226.
142. Gutierrez-Fernandez M, Rodrguez-Frutos B, Alvarez-Grech J, Vallejo-Cremades MT, Exposito-Alcaide M, Merino J et al. Functional recovery after hematic administration of allogenic mesenchymal stem cells in acute ischemic stroke in rats. Neuroscience 2011; 175: 394-405.
143. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54-63.
144. Allers C, Sierralta WD, Neubauer S, Rivera F, Minguell JJ, Conget PA. Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice. Transplantation 2004; 78: 503-508. (Pubitemid 39097094)
145. Erices AA, Allers CI, Conget PA, Rojas CV, Minguell JJ. Human cord blood-derived mesenchymal stem cells home and survive in the marrow of immunodeficient mice after systemic infusion. Cell Transplantation 2003; 12: 555-561. (Pubitemid 37204412)
146. Shen LH, Li Y, Chen J, Cui Y, Zhang C, Kapke A et al. One-year follow-up after bone marrow stromal cell treatment in middle-aged female rats with stroke. Stroke 2007; 38: 2150-2156. (Pubitemid 47012282)
147. Sjoholm I, Edman P. Acrylic microspheres in vivo. I. Distribution and elimination of polyacrylamide microparticles after intravenous and intraperitoneal injection in mouse and rat. J Pharmacol Exp Ther 1979; 211: 656-662. (Pubitemid 10177935)
148. Walczak P, Zhang J, Gilad AA, Kedziorek DA, Ruiz-Cabello J, Young RG et al. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke 2008; 39: 1569-1574.
149. Grieve SM, Bhindi R, Seow J, Doyle A, Turner AJ, Tomka J et al. Microvascular obstruction by intracoronary delivery of mesenchymal stem cells and quantification of resulting myocardial infarction by cardiac magnetic resonance. Circ Heart Fail 2010; 3: e5-e6.
150. Willing AE, Lixian J, Milliken M, Poulos S, Zigova T, Song S et al. Intravenous versus intrastriatal cord blood administration in a rodent model of stroke. J Neurosci Res 2003; 73: 296-307. (Pubitemid 36918093)
151. Chen J, Ye X, Yan T, Zhang C, Yang X-P, Cui X et al. Adverse effects of bone marrow stromal cell treatment of stroke in diabetic rats. Stroke 2011; 42: 3551-3558.
152. King AJF. The use of animal models in diabetes research. Br J Pharmacol 2012; 166: 877-894.
153. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57: 874-882. (Pubitemid 40798626)
154. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010; 28: 1099-1106.
155. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007; 67: 9142-9149. (Pubitemid 47535900)
156. Bhasin A, Srivastava MVP, Kumaran SS, Mohanty S, Bhatia R, Bose S et al. Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc Dis Extra 2011; 1: 93-104.
157. Bhasin A, Padma Srivastava MV, Mohanty S, Bhatia R, Kumaran SS, Bose S. Stem cell therapy: A clinical trial of stroke. Clin Neurol Neurosurg 2012 pii: S0303-8467(12)00533-1-1.
158. The STEPS Participants. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 2009; 40: 510-515.
159. Savitz SI, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L. Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. Stroke 2011; 42: 825-829.
160. Stroke Therapy Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30: 2752-2758.
161. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB et al. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke 2011; 42: 2645-2650.
162. Kleim JA, Jones TA. Principles of experience-dependent neural plasticity: implications for rehabilitation after brain damage. J Speech Lang Hear Res 2008; 51: S225-S239. (Pubitemid 351206588)
163. Biernaskie J, Chernenko G, Corbett D. Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. J Neurosci 2004; 24: 1245-1254. (Pubitemid 38177031)
164. Ren J, Kaplan PL, Charette MF, Speller H, Finklestein SP. Time window of intracisternal osteogenic protein-1 in enhancing functional recovery after stroke. Neuropharmacology 2000; 39: 860-865. (Pubitemid 30103689)
165. Grotta J, Bratina P. Subjective experiences of 24 patients dramatically recovering from stroke. Stroke 1995; 26: 1285-1288.
166. Fisher M, Ratan R. New perspectives on developing acute stroke therapy. Ann Neurol 2003; 53: 10-20. (Pubitemid 36083824)
167. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002; 33: 2123-2136. (Pubitemid 34840080)
168. Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M et al. Stroke: working toward a prioritized world agenda. Stroke 2010; 41: 1084-1099.
169. Cramer SC. Stratifying patients with stroke in trials that target brain repair. Stroke 2010; 41: S114-S116.
170. Nouri S, Cramer SC. Anatomy and physiology predict response to motor cortex stimulation after stroke. Neurology 2011; 77: 1076-1083.
171. Stinear CM, Barber PA, Smale PR, Coxon JP, Fleming MK, Byblow WD. Functional potential in chronic stroke patients depends on corticospinal tract integrity. Brain 2007; 130: 170-180. (Pubitemid 46026233)
172. Riley JD, Le V, Der-Yeghiaian L, See J, Newton JM, Ward NS et al. Anatomy of stroke injury predicts gains from therapy. Stroke 2011; 42: 421-426.
173. Lai S-M, Duncan PW, Keighley J, Johnson D. Depressive symptoms and independence in BADL and IADL. J Rehabil Res Dev 2002; 39: 589-596. (Pubitemid 35388078)
174. Gillen R, Tennen H, McKee TE, Gernert-Dott P, Affleck G. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. Arch Phys Med Rehabil 2001; 82: 1645-1649. (Pubitemid 33126667)
175. Cramer SC, Parrish TB, Levy RM, Stebbins GT, Ruland SD, Lowry DW et al. Predicting functional gains in a stroke trial. Stroke 2007; 38: 2108-2114. (Pubitemid 47012276)
176. Uchino K, Billheimer D, Cramer SC. Entry criteria and baseline characteristics predict outcome in acute stroke trials. Stroke 2001; 32: 909-916. (Pubitemid 32285160)
177. Cramer SC. Brain repair after stroke. N Engl J Med 2010; 362: 1827-1829.
178. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 1982; 217: 855-857. (Pubitemid 12042921)
179. Wiesel TN, Hubel DH. Ordered arrangement of orientation columns in monkeys lacking visual experience. J Comp Neurol 1974; 158: 307-318.
180. Cramer SC, Koroshetz WJ, Finklestein SP. The case for modality-specific outcome measures in clinical trials of stroke recovery-promoting agents. Stroke 2007; 38: 1393-1395. (Pubitemid 351664265)
181. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 2009; 3: 63-70.
182. Cui X, Chen J, Zacharek A, Li Y, Roberts C, Kapke A et al. Nitric oxide donor upregulation of stromal cell-derived factor-1/chemokine (CXC motif) receptor 4 enhances bone marrow stromal cell migration into ischemic brain after stroke. Stem Cells 2007; 25: 2777-2785. (Pubitemid 350127862)
183. Liu H, Honmou O, Harada K, Nakamura K, Houkin K, Hamada H et al. Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia. Brain 2006; 129: 2734-2745. (Pubitemid 44522106)
184. Shen LH, Li Y, Chen J, Zhang J, Vanguri P, Borneman J et al. Intracarotid transplantation of bone marrow stromal cells increases axon-myelin remodeling after stroke. Neuroscience 2006; 137: 393-399. (Pubitemid 43031506)
185. Zhang C, Li Y, Chen J, Gao Q, Zacharek A, Kapke A et al. Bone marrow stromal cells upregulate expression of bone morphogenetic proteins 2 and 4, gap junction protein connexin-43 and synaptophysin after stroke in rats. Neuroscience 2006; 141: 687-695. (Pubitemid 44066656)
186. Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med 2009; 3: 363-383.
187. Leu S, Lin Y-C, Yuen C-M, Yen C-H, Kao Y-H, Sun C-K et al. Adipose-derived mesenchymal stem cells markedly attenuate brain infarct size and improve neurological function in rats. J Transl Med 2010; 8: 63.
188. Chen J, Shehadah A, Pal A, Zacharek A, Cui X, Cui Y et al. Neuroprotective effect of human placenta-derived cell treatment of stroke in rats. Cell Transplant 2012; 22: 871-879.
189. Egashira Y, Sugitani S, Suzuki Y, Mishiro K, Tsuruma K, Shimazawa M et al. The conditioned medium of murine and human adipose-derived stem cells exerts neuroprotective effects against experimental stroke model. Brain Res 2012; 1461: 87-95.
190. Yang Y-C, Liu B-S, Shen C-C, Lin C-H, Chiao M-T, Cheng H-C. Transplantation of adipose tissue-derived stem cells for treatment of focal cerebral ischemia. Curr Neurovasc Res 2011; 8: 1-13.